{"id":"NCT02025751","sponsor":"Evoke Pharma","briefTitle":"Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis","officialTitle":"Phase 3 Companion Study of Intranasal Metoclopramide in Men With Symptomatic Diabetic Gastroparesis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-04","primaryCompletion":"2016-08","completion":"2016-10","firstPosted":"2014-01-01","resultsPosted":"2020-07-07","lastUpdate":"2020-07-07"},"enrollment":53,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Gastroparesis"],"interventions":[{"type":"DRUG","name":"Metoclopramide Nasal Spray","otherNames":[]},{"type":"DRUG","name":"Placebo Nasal Spray","otherNames":["Vehicle"]}],"arms":[{"label":"Metoclopramide Nasal Spray","type":"EXPERIMENTAL"},{"label":"Placebo Nasal Spray","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is evaluate the safety and efficacy of Metoclopramide Nasal Spray compared to placebo in reducing the symptoms of diabetic gastroparesis in adult men.","primaryOutcome":{"measure":"Gastroparesis Symptom Assessment (GSA), a Patient Reported Outcome Measure","timeFrame":"Change from the Baseline Period to Week 4 in Daily Total Score (Intent-to Treat Population)","effectByArm":[{"arm":"Metoclopramide Nasal Spray","deltaMin":-0.751,"sd":0.4673},{"arm":"Placebo Nasal Spray","deltaMin":-0.657,"sd":0.9042}],"pValues":[{"comp":"OG000 vs OG001","p":"0.597"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":7},"locations":{"siteCount":49,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":26},"commonTop":["Throat irritation","Liver palpable","Platelet count decreased","Malaise","Pyrexia"]}}